IP & Copyright
Supreme Court Hears 'Skinny Label' Case: What's Next?
The Supreme Court's oral arguments in *Hikma Pharmaceuticals USA v. Amarin Pharma, Inc.* have thrown a wrench into expectations for the generic drug industry, hinting at a potential reinforcement of existing patent law rather than a radical overhaul.